Anvisa approves Ozivy, the first Brazilian medication similar to Ozempic
The National Health Surveillance Agency (Anvisa) recently approved the commercialization of Ozivy in Brazil. This new medication, produced by the Brazilian pharmaceutical company EMS, is a synthetic analog of semaglutide. It works similarly to Ozempic, a drug that has become world-famous in the treatment of type 2 diabetes and obesity management.
Ozivy is the first product of its kind developed by a national company to receive authorization from the regulatory agency. The technology used allows it to mimic the GLP-1 hormone, which helps control blood sugar levels and increases the feeling of satiety in the body. This approval is seen as an important milestone for the country's pharmaceutical industry.
Currently, the market for these medications is dominated by the Danish company Novo Nordisk, the manufacturer of Ozempic and Wegovy. EMS's entry with a synthetic version is expected to increase competition in the sector. Specialists believe that the presence of a national competitor could facilitate access to treatment and diversify the options available to doctors and patients.
To receive the seal of approval, Ozivy underwent rigorous quality and safety tests required by Anvisa. The agency evaluated the formula's efficacy to ensure that the medication delivers what it promises without posing unnecessary health risks. This oversight process is fundamental to maintaining public safety standards in Brazil.
The expectation now is that the new medication will reach pharmacies soon, although the exact date for the start of sales still depends on commercial and distribution procedures. The national production of high-tech medicines represents an advancement for Brazilian science and reinforces the country's capacity to develop complex treatments.